[Inflammatory bowel disease: anti-TNF strategies and beyond].
Hoffmann
J C
JC
Medizinische Klinik I mit Schwerpunkt Gastroenterologie/Infektiologie/Rheumatologie, Charité, Universitätsmedizin Berlin, Campus Benjamin Franklin. joerg.hoffmann@charite.de
D000818:Animals; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D002986:Clinical Trials as Topic; D003093:Colitis, Ulcerative / Q000188:drug therapy* / Q000276:immunology; D003424:Crohn Disease / Q000188:drug therapy* / Q000276:immunology; D006801:Humans; D000069285:Infliximab; D018799:Intercellular Adhesion Molecule-1 / Q000187:drug effects; D000069442:Natalizumab; D010455:Peptides / Q000009:adverse effects / Q000627:therapeutic use; D019947:Receptors, Interleukin-6 / Q000037:antagonists & inhibitors; D015398:Signal Transduction / Q000187:drug effects; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000069442:Natalizumab; D010455:Peptides; D019947:Receptors, Interleukin-6; D014409:Tumor Necrosis Factor-alpha; D018799:Intercellular Adhesion Molecule-1; C092373:allotrap; D000069285:Infliximab
Chronisch entzündliche Darmerkrankungen: Anti-TNF-Strategien -- und was kommt weiter?